|
|
Anavex rapidly advances ANAVEX 2-73 for Alzheimer's disease, Phase I clinical trial progressing well
Sources News Release
http://www.sources.com/Releases/NR1357.htm
Publisher: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written: 06/07/2011
Year Published: 2011
Resource Type: Article
Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) has commenced the 30 mg dose step in its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead drug candidate for Alzheimer’s disease. This is the third of six potential dose
Abstract: Hoboken, NJ – July 6, 2011 -- Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) has commenced the 30 mg dose step in its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead drug candidate for Alzheimer’s disease. This is the third of six potential dose steps and follows the successful completion of the 1 mg and 10 mg dosing rounds. There have been no adverse effects recorded after the administration of ANAVEX 2-73 at the doses studied to date.
Trial participants are ...
To read the full release go to http://www.sources.com/Releases/NR1357.htm
Topics
|
AlterLinks
c/o Sources
© 2025.
|
|
|
|
